Representative before the EPO

Technology company logo thumb
no operation time available
Technology Company

We have observed 26 EP applications Dirk Halbig has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12712098

SELECTION OF HCV TREATMENT

IPC classification:
A61K 31/7056, A61K 31/7068, A61K 38/21, A61K 45/06, A61P 31/14, C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12769102

ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/551, A61P 31/14, C07D 487/04, C07D 519/00
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP12790564

A SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 THAT PREDICTS HCV TREATMENT RESPONSES

IPC classification:
C12Q 1/70
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12799571

INHIBITORS OF HCV NS5A

IPC classification:
A61K 38/06, A61P 31/14, C07D 233/64, C07D 237/26, C07K 5/08
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13737175

TRIAZOLE COMPOUNDS AS ANTIVIRALS

IPC classification:
A61K 31/4196, A61P 31/14, C07D 249/14, C07D 403/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
The patent has been granted
EP14702466

ANTIVIRAL TRIAZOLE DERIVATIVES

IPC classification:
A61K 31/4196, A61P 31/14, C07D 249/14, C07D 401/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP14707400

ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/4196, A61P 31/12, C07D 401/12, C07D 403/12, C07D 409/12, C07D 487/10
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP14707401

ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/4196, A61P 31/12, C07D 249/14, C07D 401/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14707410

ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/4196, A61K 31/427, A61K 31/4439, A61K 31/4745, A61K 31/501, A61P 31/00, C07D 401/12, C07D 403/12, C07D 409/12, C07D 417/12, C07D 471/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14710208

ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/12, A61K 31/4196, C07D 249/14, C07D 401/12, C07D 403/12, C07D 405/12
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
PATENT GRANTED
EP14708234

ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/4196, A61K 31/425, A61K 31/454, A61K 31/496, A61K 31/5377, A61K 31/538, C07D 249/14, C07D 401/12, C07D 403/12, C07D 405/12, C07D 411/12, C07D 413/12, C07D 417/12, C07D 491/107, C07D 495/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP14706841

N-HETEROARYL SUBSTITUTED ANILINE DERIVATIVES AS HCV-ANTIVIRALS

IPC classification:
A61K 31/4164, A61K 31/4196, A61P 31/12, C07D 263/40, C07D 271/06
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14724735

6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

IPC classification:
A61K 31/506, A61P 31/12, C07D 453/06, C07D 471/08, C07D 487/08, C07D 491/08, C07D 491/18
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
EXAMINATION IN PROGRESS
EP13152518

Single nucleotide polymorphisms that predict HCV treatment outcomes

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11717518

SINGLE NUCLEOTIDE POLYMORPHISMS THAT PREDICT HCV TREATMENT OUTCOMES

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11746515

PREDICTION OF HCV VIRAL KINETICS IN INTERFERON-FREE TREATMENT

IPC classification:
A61K 31/00, C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13152522

Single nucleotide polymorphisms that predict HCV treatment outcomes

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11713289

PREDICTION OF EARLY VIROLOGICAL RESPONSE IN HCV TREATMENT

IPC classification:
C12Q 1/70
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11746520

HETEROCYCLIC ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/4709, A61K 31/513, A61K 45/06, C07D 401/04, C07D 401/10, C07D 401/14
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11701107

4'-AZIDO-NUCLEOSIDES AS ANTI-HCV COMPOUNDS

IPC classification:
A61K 31/7072, C07H 19/067
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11738413

HETEROCYCLIC ANTIVIRAL COMPOUNDS

IPC classification:
A61K 31/517, A61K 31/519, A61P 31/14, C07D 401/04, C07D 401/14, C07D 403/04, C07D 471/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14820805

BIOMARKERS FOR HBV TREATMENT RESPONSE

IPC classification:
C12Q 1/68
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15710127

NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

IPC classification:
A61K 31/4985, A61P 31/12, C07D 487/04, C07D 498/04, C07D 513/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP15766159

STABLE, BENZYL ALCOHOL-FREE AQUEOUS SOLUTION FORMULATIONS CONTAINING ALPHA-TYPE INTERFERON

IPC classification:
A61K 9/08, A61K 38/21, A61K 47/10, A61K 47/18, A61K 47/26, A61K 47/60
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP15813759

BIOMARKERS FOR HBV TREATMENT RESPONSE

IPC classification:
C12Q 1/68, C12Q 1/70
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
Request for examination was made
EP16700562

PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES

IPC classification:
A61K 31/519, A61P 31/12, C07D 487/04
Applicant:
F. Hoffmann-La Roche AG
Agent:
Dirk Halbig, F. Hoffmann-La Roche AG
Status:
Request for examination was made

Please Sign in to use this feature